ArticleBreast cancer research and treatment2026
Geographic access to triple negative breast cancer clinical trials: are trials located near patients?
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGeographic proximity to clinical trials is a major barrier to trial participation, but geographic access to trials has not been specifically characterized for triple-negative breast cancer (TNBC). We evaluated the geographic distribution of TNBC treatment trials across U.S. counties and examined associated social and demographic characteristics.
methodsAll trials registered on ClinicalTrials.gov as of September 30, 2024 (n = 510,397) were queried, and active phase II and III TNBC treatment trials were identified through keyword searches. County-level population estimates from the 2018-2022 U.S. Census Bureau 5-year estimates and county adjacency data were used to evaluate trial availability and geographic access. Trial availability was examined according to sponsorship, rurality, health vulnerability, race and ethnicity, and U.S. region.
resultsWe identified 108 active TNBC trials, including 58 (54%) for metastatic and 50 (46%) for non-metastatic disease. Overall, 76% of U.S. counties had no TNBC trials, 12% had exclusively federally sponsored trials, 10% had both federally and non-federally sponsored trials, and 2% had only non-federally sponsored trials. Trial availability was significantly lower in counties with the highest health vulnerability and in rural counties, which were more likely to rely exclusively on federally sponsored trials. Counties with predominantly Black, Hispanic, and American Indian and Alaska Native populations were less likely to have TNBC trials than predominantly non-Hispanic White counties. Women in the South were more likely than women in the Northeast to have no TNBC trial available in either their county of residence or a neighboring county.
conclusionsTNBC clinical trials are geographically concentrated across the United States, with substantial disparities in access affecting rural and highly vulnerable counties, counties with predominantly racial and ethnic minority populations, and women living in the South. Federally sponsored trials may play an important role in supporting trial availability in underserved areas. Expanding the geographic distribution of TNBC trials may help improve equitable access to clinical trial participation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.